FDA Investigator: Omotunde O. Osunsanmi

- Omotunde O. Osunsanmi first started conducting FDA inspections in 2000, with the last inspection in 2022. Over that time, Omotunde O. Osunsanmi has conducted 203 inspections at 132 companies across 145 sites.

Documents

FDA 483 Broekman Institute, Someren | March 2020

Available - $199
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 BioConnection B.V, Oss | March 2020

Available - $199
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Dynavax, Dusseldorf | March 2019

Available - $199
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 National Genetics Institute, Los Angeles | 2022

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Dendreon Pharmaceuticals LLC, Seal Beach | 2019

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 GSK Vaccines S.r.l, Sovicille | 2019

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 GlaxoSmithKline Vaccines Srl, Siena | 2019

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Hologic Ltd., Livingston | 2019

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Bayer Healthcare, LLC, Berkeley | 2018

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 MedImmune U.K. Limited, Liverpool | 2018

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Sanofi Winthrop Industrie, Le Trait | 2018

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Wyeth Pharmaceutical Division of Wyeth Holdings LLC, Sanford | 2018

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Baxalta US Inc., Social Circle | 2018

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Baxalta US Inc., Thousand Oaks | 2018

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Sanofi Pasteur Limited - Cannaught Campus, North York | 2017

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Novartis Pharma AG, Basel | 2017

Out-of-stock
Omotunde O. Osunsanmi
Human Drug Form 483

FDA 483 Seqirus A CSL Company, Liverpool | 2017

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Ajinomoto Althea, Inc., San Diego | 2017

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Merck Sharp & Dohme Corp., West Point | 2017

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Novo Nordisk A/S, Bagsvard | 2017

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 National Genetics Institute, Los Angeles | 2017

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 MP Biomedicals Asia Pacific Ptd Ltd, Singapore | 2016

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Kedrion S.p.A., Gallicano | 2016

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Catalent Pharma Solutions Limited, Swindon | 2016

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Wyeth Pharmaceutical Division of Wyeth Holdings LLC, Pfizer, Sanford | 2016

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Sanquin Plasma Supply Foundation, Amsterdam | 2016

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Swedish Orphan Biovitrum AB, Stockholm | 2016

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Baxalta, Orth An Der Donau | 2016

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

FDA 483 Sanochemia Pharmazeutika Ag, Neufeld An Der Leitha | 2016

Out-of-stock
Omotunde O. Osunsanmi
Biologic Form 483

Co-Investigators (77)